A note to our readers: Patent Docs apologizes to our
readers for the recent Court Report hiatus. This Court Reporter was deeply immersed in very intensive preliminary
injunction proceedings and has just now been able to come up for air. We will catch our readers up in the next few
postings. Patent Docs thanks our readers
for their patience.
Purdue Pharma LP et. al. v. KV Pharmaceuticals Co. and Actavis Totowa LLC
1:07-cv-00032; filed January 16, 2007 in the District Court of Delaware
Infringement of U.S. Patent Nos. 5,508,042 ("Controlled Release Oxycodone Compositions," issued April 16, 1996), 5,549,912 (same title, issued August 27, 1996), and 5,656,295 (same title, issued August 12, 1997) following a paragraph IV certification as part of KV's and Actavis' filing of an ANDA to manufacture a generic version of Purdue Pharma's OxyContin® (controlled release oxycodone hydrochloride, used to treat pain). View the complaint here.
Celgene Corp. v. Barr Laboratories, Inc. et. al.
2:07-cv-00286; filed January 18, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 6,045,501 ("Methods for Delivering a Drug to a Patient While Preventing the Exposure of a Foetus or Other Contraindicated Individual to the Drug," issued April 4, 2000), 6,561,976 (same title, issued May 13, 2003), 6,315,720 ("Methods for Delivering a Drug to a Patient While Avoiding the Occurrence of an Adverse Side Effect Known or Suspected of Being Caused by the Drug," issued November 13, 2001), 6,561,977 ("Methods for Delivering a Drug to a Patient While Restricting Access to the Drug by Patients for Whom the Drug May be Contraindicated," issued May 13, 2003), 6,755,784 (same title, issued June 29, 2004), 6,869,399 (same title, issued March 22, 2005), and 7,141,018 (same title, issued November 28, 2006) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of Celgene's Thalomid® (thalidomide, used to treat multiple myeloma and erythema nodosum leprosum). View the complaint here.
Syngenta Biotechnology, Inc. et. al. v. DeKalb Genetics Corporation et. al.
1:07-cv-00038; filed January 19, 2007 in the District Court of Delaware
Declaratory judgment of invalidity and noninfringement of U.S. Patent No. 5,554,798 ("Fertile Glyphosate-Resistant Transgenic Corn Plants," issued September 10, 1996). The '798 patent covers a genetically modified corn line exhibiting glyphosate resistance. View the complaint here.
Monsanto Co. et. al. v. Jarrell
4:07-cv-00118; filed January 19, 2007 in the Eastern District of Missouri
Monsanto Co. et. al. v. Dorris
1:07-cv-00012; filed January 22, 2007 in the Eastern District of Missouri
The complaints in these two cases are quite comparable. Infringement of U.S. Patent Nos. 5,352,605 ("Chimeric Genes for Transforming Plant Cells Using Viral Promoters," issued October 4, 1994) and RE39,247 ("Glyphosate-tolerant 5-enolpyruvylshikimate-3-phosphate Synthases," issued August 22, 2006) based on defendant's use of soybean seed produced from earlier planted Roundup Ready® soybean seed. View the Jarrell complaint here.
Shire LLC v. Sandoz, Inc.
1:07-cv-00197; filed January 26, 2007 in the District Court of Colorado
Infringement of U.S. Patent Nos. 6,322,819 ("Oral pulsed dose drug delivery system," issued November 27, 2001) and 6,605,300 (same title, issued August 12, 2003) following a paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Shire's Adderall XR® (a combination of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, and amphetamine sulfate, used to treat attention deficit hyperactivity disorder). View the complaint here.
Sanofi-Aventis et. al. v. Watson Pharmaceuticals, Inc. et. al.
2:07-cv-00443; filed January 26, 2007 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,514,531 ("Controlled-release Dosage Forms Comprising Zolpidem or a Salt Thereof," issued February 4, 2003) following a paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of Sanofi-Aventis' Ambien CR® (controlled release zolpidem tartrate, used to treat insomnia). View the complaint here.
Comments